- 1,699studies in the library match, of 29,380
- 365name it in the title
- 1976–2026years published
- 1,653peer-reviewed articles
The query: title or abstract mentions "Alzheimer" or "dementia" AND "survival", "life expectancy", "time to death", "years after/from diagnosis", "all-cause mortality", "cause of death", "place of death", "end of life", "palliative" or "hospice", matched case-insensitively against each record's title and abstract (its summary field) in alzhub's library of 29,380 study records, as of 2026-11-08. Every count on this page comes from that match. The matched list as JSON.
Survival studies follow people from diagnosis (or from symptom onset) and report the median time to death and the factors linked to shorter or longer survival: age at diagnosis, sex, how advanced the disease was when diagnosed, other illnesses, and dementia type. Because many people are diagnosed years after symptoms began, survival from diagnosis understates survival from onset.
Alzhub's library reports what these papers found; it does not predict any person's course. The figures quoted below are group medians and ranges from the studies named.
This page describes what published research in alzhub's library reports. It is not medical advice and does not apply to any one person: a doctor who knows the person's history is the only one who can say what a result or a treatment means for them.
What the studies report, in their own words
Whole sentences copied from the abstract or key findings of the highest-scoring matched studies, chosen because they mention the subject and give a figure. 8 of the 1,699 matched records are quoted; each links to its study page and from there to the paper.
“Conclusions In a large placebo-controlled randomized trial, we found that pantoprazole is not associated with any adverse event when used for 3 years, with the possible exception of an increased risk of enteric infections.”
“Meta-analyses indicated that each 5-year increase in DNA methylation age was associated an 8 to 15% increased risk of mortality.”
“A total of 917 participants had a mean baseline age of 67.4 years (SD 12.1), 49.4% were female, and 48.6% self-identified as Black.”
“Over the mean (SD) follow-up of 2.27 (1.22) years, ADCS-ADL Inventory scores declined by 3.15 units (95% CI, 0.92 to 5.39; adjusted P = .03) less in the alpha tocopherol group compared with the placebo group.”
“Results The pooled prevalence of OD in 39 studies with 31,488 participants was 46% associated with higher pooled OR for risk of pneumonia 2.07 (95% CI, 1.58-2.72), malnutrition 2.21 (95% CI, 1.43-3.41), and mortality 2.73 (95% CI, 1.62-4.60).”
“The risk of death from any cause was 12.7 events per 1000 person-years in the aspirin group and 11.1 events per 1000 person-years in the placebo group (hazard ratio, 1.14; 95% confidence interval [CI], 1.01 to 1.29).”
“Results Age-standardized prevalence for those aged ≥60 years varied in a narrow band, 5%-7% in most world regions, with a higher prevalence in Latin America (8.5%), and a distinctively lower prevalence in the four sub-Saharan African regions (2%-4%).”
“Results In this meta-analysis, the estimate of age at onset was 53.8 years (95% CI, 53.1-54.5 years; n = 2695); the estimate of age at death, 58.4 years (95% CI, 57.2-59.7 years; n = 324); and the estimate of disease duration, 4.6 years (95% CI, 3.7-5.5 years; n = 226).”
What kind of evidence it is
By study design
| Design (as recorded) | Studies |
|---|---|
| Systematic review or meta-analysis | 67 |
| Randomised controlled trial | 32 |
| Other clinical trial | 7 |
| Cohort or longitudinal study | 245 |
| Case-control study | 8 |
| Cross-sectional study | 79 |
| Other recorded design | 17 |
| No design recorded | 1,244 |
The design is the one named in alzhub's record for the study; a record with none is counted as "no design recorded".
By year
| Year | Studies | Share |
|---|---|---|
| 2026 | 116 | |
| 2025 | 203 | |
| 2024 | 50 | |
| 2023 | 48 | |
| 2022 | 78 | |
| 2021 | 80 | |
| 2020 | 94 | |
| 2019 | 93 | |
| 2018 | 100 | |
| 2017 | 85 | |
| 2016 and earlier | 752 |
Other counts within the matched set
| Peer-reviewed articles | 1,653 |
| Marked open access in the record | 521 |
| Rated "high" evidence strength in alzhub's summary | 140 |
| Rated "moderate" evidence strength in alzhub's summary | 354 |
| Rated "low" evidence strength in alzhub's summary | 1,197 |
| No evidence-strength rating | 8 |
| Records stating a participant count | 580 |
| Median participants (those records) | 345 |
| Largest participant count | 5,553,960 |
Within the 1,699 matched studies
| Studies… | Count | Rule |
|---|---|---|
| …that report median survival or survival time | 638 | the abstract also contains "survival" |
| …that mention palliative or hospice care | 614 | the abstract also contains "palliative" or "hospice" |
| …that mention age at diagnosis or onset | 29 | the abstract also contains "age at diagnosis" or "age at onset" |
The 10 highest-scoring matched studies
Title matches first, then by alzhub's usefulness score, which rates a study's design, journal, evidence and recency, not whether its result is good news.
- Palliative care interventions in advanced dementia
- Palliative care interventions in advanced dementia
- Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: A systematic review and meta-analysis
- Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
- Palliative Care Program for Community-Dwelling Individuals With Dementia and Caregivers: The IN-PEACE Randomized Clinical Trial
- Me & My Wishes: Concordance of End-of-Life Preferences between Residents with Dementia, Family, and Staff
- Nursing Interventions in Palliative Care for Advanced Dementia: A Systematic Review of Symptom, Relief, Comfort, and Caregiver Support
- Referral criteria to specialist palliative care for patients with dementia: A systematic review
- Palliative care in advanced dementia; A mixed methods approach for the development of a complex intervention
- Implementation of Specialist Palliative Care and Outcomes for Hospitalized Patients with Dementia
Systematic reviews and meta-analyses in the set
67 of the matched records are recorded as a systematic review, meta-analysis or umbrella review; the highest-scoring not already listed above:
- WMH and long-term outcomes in ischemic stroke: A systematic review and meta-analysis
- The epigenetic clock as a predictor of disease and mortality risk: a systematic review and meta-analysis
- Preventing delirium: should non-pharmacological, multicomponent interventions be used? A systematic review and meta-analysis of the literature
- Prevalence of Oropharyngeal Dysphagia and Risk of Pneumonia, Malnutrition, and Mortality in Adults Aged 60 Years and Older: A Meta-Analysis
- The global prevalence of dementia: a systematic review and metaanalysis
Newest matched studies
- Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival
- The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration
- Evaluating a primary care pharmacist-led intervention to reduce opioid use for persistent non-cancer pain: the PROMPPT cluster randomised controlled trial protocol
- Beyond Glycemic Control: The Pleiotropic Role of GLP-1RAs and Melatonin in Combating Neuroinflammation and Mitochondrial Dysfunction
- Cerebrospinal fluid α-synuclein seed amplification assay positivity identifies a prognostically distinct subgroup in amyotrophic lateral sclerosis
Journals with the most matched studies
| Journal | Studies |
|---|---|
| Journal of the American Geriatrics Society | 74 |
| Neurology | 55 |
| Palliative medicine | 45 |
| Journal of palliative medicine | 36 |
| Journal of pain and symptom management | 35 |
Questions
- How long do people live after an Alzheimer's diagnosis?
- It varies widely with age at diagnosis, stage at diagnosis, other illnesses and dementia type, and the studies below report group medians, not individual predictions. Someone diagnosed early and young typically lives longer than the median; someone diagnosed late and old, shorter.
- What usually causes death in Alzheimer's?
- In the late stage the disease affects swallowing, movement and immunity, so pneumonia and other infections are the most commonly recorded causes. The papers in the set that studied cause of death give the breakdown they found.
- How many studies on life expectancy after diagnosis does alzhub hold?
- 1,699 of the 29,380 study records in alzhub's library match the query "title or abstract mentions "Alzheimer" or "dementia" AND "survival", "life expectancy", "time to death", "years after/from diagnosis", "all-cause mortality", "cause of death", "place of death", "end of life", "palliative" or "hospice""; 365 of them name it in the title. Counted from the records when this page was built.
- What kinds of study are they?
- 67 systematic review or meta-analysis, 32 randomised controlled trials, 7 other clinical trials, 245 cohort or longitudinal studys, 8 case-control studys, 79 cross-sectional studys; 1,244 record no design.
- What is the most recent study in the set?
- "Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival" (Research Square, 2026), the newest by publication date among the matched records.
- Which journals publish most on it?
- Journal of the American Geriatrics Society (74); Neurology (55); Palliative medicine (45), counted across the matched records.
Read on
- Early, middle and late stagesWhat changes at each stage and what to expect.
- Legal and financial planningAdvance directives and what care costs.
- Hospital stays and deliriumA common late-stage complication.